| Drug Name |
Vilazodone |
| Drug ID |
BADD_D02456 |
| Description |
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622]. |
| Indications and Usage |
Vilazodone is approved for treatment of acute episodes of major depression. Labeling of vilazodone describes an increased risk of suicidal thoughts in children, adolescents and young adults. The use of vilazodone in pediatrics is not indicated. Its use with monoamine oxidase inhibitors (MAOI) is contraindicated due to increased risk of serotonin syndome. Once the MAOI is discontinued, a 14-day washout period must pass before starting vilazodone. |
| Marketing Status |
Not Available |
| ATC Code |
N06AX24 |
| DrugBank ID |
DB06684
|
| KEGG ID |
D09698
|
| MeSH ID |
D000069503
|
| PubChem ID |
6918314
|
| TTD Drug ID |
D0X6BV
|
| NDC Product Code |
Not Available |
| Synonyms |
Vilazodone Hydrochloride | Hydrochloride, Vilazodone | 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) | Vilazodone HCl | HCl, Vilazodone | Viibryd | EMD 68843 | 68843, EMD | EMB-68843 | EMB 68843 | EMB68843 | Vilazodone | 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide |
